A dual-pathway (PI3K/mTOR + MAPK) HA conjugate targeting high-CD44 tumors, including KRAS G12D-mutant PDAC, TNBC, and mCRC.
• Clinical Data: Phase I in mCRC showed prolonged PFS, improved DCR, and strong tolerability
• Differentiation: >300 hrs tumor retention, 10x dose reduction with maintained efficacy
• Next Steps: ODD application for PDAC; expansion to other tumor types
Hyaluronic acid (HA), a biocompatible linear polysaccharide, has recently been utilized as a drug delivery vehicle. HA conjugated drugs developed by HylTargis™ platform are drug delivery systems for targeted transport of anticancer therapeutics to tumor cells through interaction of HA with the cells CD44 receptor.
Nimesulide, one of the most potent non-steroidal anti-inflammatory drugs (NSAIDs) studied so far in cancer chemotherapy, has been shown to inhibit tumor progression in several in vitro and in vivo studies.
CA102N is the conjugation of HA and a derivative of Nimesulide which not only targets tumor cell surface receptor CD44, but also undergoes enzymatic degradation within the lysosomal compartment eventually resulting in tumor growth inhibition.
CA102N IV infusion solution is used as a therapy dosage for treatment of patients with colorectal cancer.